XRAY
Dentsply Sirona Inc
Dentsply Sirona Inc historical holders
total: 7
Meritage Group Dentsply Sirona Inc transactions over time
- Total transactions:
- 10
- New positions:
- 3
- Sold out:
- 3
- Added:
- 1
- Reduced:
- 3
- Held since:
- 2022 Q3
- Held for:
- 4 quarters
- Latest activity:
- 2023 Q3
Nathaniel Simons has been an institutional investor in Dentsply Sirona Inc (XRAY) since 2020 Q1. According to 2026 Q1 report, Nathaniel Simons doesn't hold any shares. The fund/company first acquired XRAY in 2020 Q1, initially purchasing 9,428 shares. Nathaniel Simons later completely sold out the position and reinvested in XRAY again in 2022 Q3. Since the initial investment, Meritage Group has made 9 more transactions in this position.
When did Nathaniel Simons exit their XRAY position?
Nathaniel Simons no longer holds Dentsply Sirona Inc (XRAY). They sold off their entire position in 2023 Q3, closing out an investment that began in 2020 Q1.
When did Nathaniel Simons first invest in XRAY?
Nathaniel Simons first invested in Dentsply Sirona Inc (XRAY) in 2020 Q1 at the reported quarter-end price of $38.82 per share, acquiring 9,428 shares in their initial purchase.
What is Nathaniel Simons's average cost basis for XRAY?
Based on historical transaction data, Nathaniel Simons's estimated cost basis for Dentsply Sirona Inc (XRAY) is approximately $28.48 per share. This represents their average reported price* across all buy transactions.
Has Nathaniel Simons reinvested in XRAY after selling?
Yes, Nathaniel Simons has shown renewed interest in Dentsply Sirona Inc (XRAY). After completely selling their position, they reinitiated an investment in 2022 Q3, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $28.48
- Weighted AVG sell price:
- $39.85
XRAY transactions history by Meritage Group
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q3
|
0.00%
|
0
|
$39.98
|
|
-100% (-5,753)
|
-0.01%
|
|
2023 Q2
|
0.01%
|
5,753
|
$39.98
|
$230,000
|
-8.60% (-541)
|
-0%
|
|
2023 Q1
|
0.01%
|
6,294
|
$39.24
|
$247,000
|
-16.99% (-1,288)
|
-0%
|
|
2022 Q4
|
0.01%
|
7,582
|
$31.79
|
$241,000
|
+2.10% (+156)
|
+0%
|
|
2022 Q3
|
0.01%
|
7,426
|
$28.41
|
$211,000
|
new
|
+0.01%
|
|
2021 Q2
|
0.00%
|
0
|
$63.84
|
|
-100% (-3,540)
|
-0%
|
|
2021 Q1
|
0.00%
|
3,540
|
$63.84
|
$226,000
|
-48.94% (-3,393)
|
-0%
|
|
2020 Q4
|
0.01%
|
$52.36
|
new
|
|||
|
2020 Q2
|
0.00%
|
$38.82
|
-100% (-9,428)
|
|||
|
2020 Q1
|
0.01%
|
$38.82
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.